| INTRODUCTION
Colorectal cancer (CRC) is diagnosed in more than 140 000 people in the US each year, leading to nearly 51 000 deaths annually. 1 Although CRC is one of the best-understood neoplasms from a genetic perspective, [2] [3] [4] this disease remains the second most common cause of cancer-related death. Decades of research have identified two major genetic classifications for CRC including microsatellite instability (MSI), and chromosomal instability (CIN). [5] [6] [7] MSI is characterized by either germline mutations of DNA mismatch repair (MMR) genes associated with the hereditary CRC condition Lynch syndrome 8 or by hypermethylation-related inactivation of at least one of the four MMR genes (also known as CpG island methylator phenotype), which is responsible for 20% of sporadic CRC. 7 In both the hereditary and sporadic cases, deficient MMR (dMMR) allows small base pair mistakes to escape repair and leads to somatic alterations in nucleotide repeat sequences called microsatellites. 9 MSI may affect the function of tumor suppressor genes or oncogenes through mutations, and this hypermutator phenotype results in genomic rather than chromosomal instability. 9, 10 Brooke R. Druliner and Xiaoyang Ruan contributed equally.
However, the majority of CRC exhibit proficient MMR (pMMR) and are microsatellite stable (MSS), but exhibit chromosome instability (CIN) and have high amounts of loss of heterozygosity (LOH). Most sporadic CRC cases, in which there is no family history of CRC, are CIN. [11] [12] [13] [14] The genetic reasons for association of sporadic CRC with CIN are complex, and may partly be attributable to somatic APC mutations. 15 However, aberrant crypt foci that are very early lesions in CRC carcinogenesis do exhibit LOH that is independent of somatic APC mutations. 16 The presence of some CIN features have been evaluated in sporadic CRC with LOH 11, 14, [16] [17] [18] [19] or copy number variation (CNV) analyses. 12, 13 The majority of the LOH studies compare the somatic allelotypes of CRC (or its putative precursors) to those of corresponding adjacent or distant normal (non-tumor) colon tissue, under the assumption that morphologically and histologically normal colon tissues are genetically normal. 11, 14, [16] [17] [18] [19] This assumption may not hold, as normal colon mucosa from sporadic CRC patients exhibit monosomy, polysomy, and aneusomy on several chromosome arms shown by FISH. 12 In addition, a significant amount of genetic aberrations in CRC have been found in normal colon tissue. 12 Indeed, the method may underestimate the actual amount of genetic aberrations, given that Calhoun et al 20 demonstrated
that copy number based methods (eg FISH, array-CGH) detect at maximum 47.2% of all forms of LOH.
The majority of CRC arises from a non-malignant precursor lesion called an adenomatous polyp. [21] [22] [23] [24] It has been shown that CRC
develops from an accumulation of genetic aberrations that can begin in the normal colon and progresses through an adenomatous polyp to cancer. 2, 25, 26 Currently, molecular features that characterize these precursor polyps as being at high risk for malignant transformation are currently limited, and LOH and CNV analyses are particularly limited in polyps that are associated with cancer. [27] [28] [29] [30] [31] We infer from these pioneering works that a broad spectrum of genetic aberrations may exist in morphologically and histologically non-malignant (either normal or polyp) colon tissue in sporadic CRC patients. Therefore, a more comprehensive evaluation of these aberrations is warranted. To this end, we used high-density SNParray data from The Cancer Genome Atlas (TCGA) to detect genetic aberrations (both LOH and CNV) in matched peripheral blood and normal colon from sporadic CRC patients. The types of genetic aberrations we evaluated included classic LOH (copy loss LOH, CL-LOH), copy neutral LOH (CN-LOH), copy gain LOH (CG-LOH), and CNV (copy gain and homozygous deletion).
To validate the findings in the TCGA data, we examined specific LOH and CNV features in an independent set of 13 patients that were subjected to Whole Genome Sequencing (WGS). In addition to the blood, normal colon, and CRC tissue, these patients also included the corresponding precursor adenomatous polyp tissue. We propose that a systematic analysis of blood, normal colon, polyp, and corresponding tumor will help to identify potentially clinically valuable genetic markers for both sporadic CRC diagnosis and risk assessment.
Importantly, identifying genetic markers that are aberrant and detectable in the patient's blood, normal colon, or polyp could advance screening and detection opportunities. 
| Functional SNP analysis
Genotypes were called by using BirdSuite (version 1.5.5), which estimates allele specific genotype by considering both common and rare CNV regions.
The Affymetrix annotation file (genome version NCBI37/hg19) was used to annotate the probe-set. All of the 45 samples from the 15 patients have SNP call rate > = 95% (mean = 99.3%, min = 97.7%).
For each SNP, we treated the major allele as reference and the minor allele as alternative (using allele frequency from CEU popula- Tissues were macrodissected as described previously. 28 Briefly, a hematoxylin and eosin guide slide was reviewed and marked by a pathologist, and areas of normal epithelium, polyp or cancer identified.
DNA was extracted by the PureGene method, and was quantified on the Qubit Fluorometer.
| Whole genome sequencing (WGS) and analysis
Library construction, sequencing and initial processing of WGS data was performed as described previously. 28 All samples were sequenced on the Illumina HiSeq X instruments resulting in 150 base pair, paired-end reads to meet a goal of 30x average coverage.
Using the Picard Informatics Pipeline, all data from a particular sample was aggregated into a single BAM file which included all reads, all bases from all reads, and original/vendor-assigned quality scores. The raw data in BAM file format for the WGS data analyzed in this manuscript are available in the dbGaP database with Study Accession number: phs001384.v1.p1. The study report page can be accessed at:
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi? study_id = phs001384.v1.p1
Accession numbers for each individual WGS BAM file are located with the sample and tissue ID in Table S8 . Table 1 ).
The primary difference seen between normal colon tissue and blood was CN-LOH, which accounted for an average of 60% (median 63%) of all LOH and CNV in the normal colon tissues (SD = 36%). The average length of CN-LOH in normal colon tissue was 97 kbp and ranged from 46 kbp in the 1st quantile to 122 kbp in the 3rd quantile. Figure 2 illustrates a ∼1 Mb CN-LOH region on 18q21.1 of normal colon tissue from patient A6-3807.
| High frequency of genetic aberrations on 18q in blood normal colon and tumor tissue
At the chromosome arm level, the most frequent genetic aberrations in both normal colon tissue and blood were enriched on 18q. In blood, the aberration peaked at 18q12.3 (37.2-43.5 MB) and 18q22, where six and nine patients had at least one copy gain region (mean = 140 KB, SD = 59 KB), respectively. Over the entire 18q region, 10 patients had at least two putative short regions of copy gain ( Figure 1A and Table S1 ). These were considered putative since visualization of these regions indicated only slight increase in log R ratio (data not shown).
In normal colon tissue, the aberration peaked at 18q22 (61.6-73.1 MB), where seven patients had at least one CN-LOH (mean = 91KB, SD = 71KB) detected. Over the span of the entire 18q arm, 10 patients had at least one CN-LOH, and three patients had at least one copy gain in their normal colon samples ( Figure 1B and Table S1 ). The enrichment was retained under relatively stringent criteria, which showed that five patients had at least two CN-LOH, and two patients had at least two copy gain regions (Table S1 ). This was still higher than the frequency of genetic aberration observed on other arms.
To determine whether the recurrent copy gain signals on 18q were specific to pMMR patients, we further analyzed blood samples from 24 patients with dMMR tumors using the same parameters. The result indicated that only four patients (16.7%) had two or more aberrations on 18q, which was significantly lower than pMMR patients (66.7%, P < 0.05). Visual inspection ( Figure S1 ) indicated that the blood sample of dMMR patients had more wide spread aberrations on chromosome 17, 19, and 22q than pMMR patients. In the pMMR cases, the amount of genetic aberration was much higher in tumor samples than that of normal colon tissue or blood. The highest frequency of LOH was observed on 18q, which had an average of 52% CL-LOH (SD = 4.4%) and 17% CN-LOH (SD = 4.6%) across the 15 patients ( Figure 1C and Table S2 ). Furthermore, a high frequency of copy gain was observed, in decreasing order, on 20q, 13q, 7p/q, and 8q. These arms have copy gain in more than 50% of the patients (Table S2 ).
In contrast to what was observed in normal colon tissue and blood, ( Figures 1C and S3 ). Both the whole arm and mosaic pattern aberrations were observed on other chromosome arms. A6-3807 Figures 1C and S4 ).
AA-3517 displayed complete copy loss on 1p and complete copy gain on 1q ( Figure 1C ). Homozygous deletion was relatively rare and was observed only on 8p of A6-5660 ( Figures 1C and S5 ).
3.3 | Genes with aberrations in blood, normal colon, and tumor
Analysis was conducted to determine how genetic aberrations in blood, normal colon, or tumor overlap between patients. In blood, 13
genes had genetic aberrations in ≥4 patients (Tables 2 and S3 ). The most frequent aberrations were copy gain at CCDC102B and KLHL14, both on 18q (close to the centromere) and affected six and five patients, respectively. CCDC102B also had a relatively high frequency of aberration in normal colon (Table 3 ) and topped the aberration list in tumor samples (Table 4) . Frequent CL-LOH and copy gain were also observed at 15q11.2, encompassing 11 genes (Table S3 ).
In normal colon, the most frequent genetic aberration was observed in DCC, which is on 18q21.1 and affected four patients in the form of CN-LOH, CG-LOH, and copy gain (Tables 3 and S4) . SGCZ, which is on 8p22, had CN-LOH and/or copy gain in the normal colon tissue of four patients. Fragile site gene FHIT (FRA3B), DOK6 (FRA18C), and DAB1
(FRA1L/1B) had aberrations in three patients. However, analysis of genes co-located with 117 fragile sites did not show significant enrichment of aberrations compared to genes in non-fragile site regions.
Among tumors, the top affected genes were CCDC102B on 18q21.1, as well as SGC and TNKS on 8p22. These genes had LOH and/or CNV, and were observed in 14 patients (Table 4) . Genetic aberrations in DCC were observed in 12 patient tumor samples.
It is noteworthy that genetic aberrations were observed for several genes that are frequently mutated in hereditary CRC. Eleven patients had somatic CL-LOH or CN-LOH in both SMAD4 and TP53, which when mutated in the germline may lead to juvenile polyposis syndrome (with or without Hereditary hemorrhagic telangiectasia overlap) or Li Fraumeni syndrome, respectively (Table 4) . Seven patients had CL-LOH, CN-LOH or copy gain in APC, which is a marker of familial adenomatous polyposis (Table 4) . However, it is remarkable that none of these genes exhibited any genetic aberrations in normal colon tissue or blood from the 15 patients. The normal colon tissue of patient A6-5660 had large amounts of CN-LOH, but exome sequencing showed no somatic or germline mutations in APC, CTNNB1
or any of the hereditary CRC risk genes shown in Table 4 .
| Concurrent gene aberrations in blood, normal colon, and tumor tissue
We found gene aberrations that were concurrent in blood and normal colon tissue, or concurrent in normal colon tissue and tumor (Table S5) .
We defined concurrent gene aberrations as being present in two sample types from the same patient and that had genomic overlap of at least one base pair in known gene regions. For blood and normal colon tissue, the most frequent concurrency occurred at 15q11, where three patients had concurrent aberrations in 12 genes (Table S5) (Table S6 ). However, none of the hereditary CRC risk genes (as shown in Table 4 ) had concurrent gene aberrations in blood and normal colon tissue, or in normal colon tissue, and tumor.
| The majority of concurrent LOH in normal colon and tumor tissues retained on the same allele
We further analyzed somatic mutations in normal colon tissue and tumor, and the germline mutations in blood of the 15 pMMR patients.
To focus on the variants with functional consequence, we selected 3394 SNPs (from Affymetrix SNP array 6.0) by restricting to those with high or moderate effects as predicted by SnpEff (see section 2 for details). The analysis aimed to shed light on the direction of LOH (ie, loss of reference or variant allele) in normal colon and tumor tissue, as well as important germline mutations in blood. We acknowledge that due to limited coverage, the analysis represents a small proportion of the whole mutation spectrum.
By comparing the genotypes across blood, normal colon and tumor tissue, we found that the majority (96.9%) of LOH, if present in both the normal colon and tumor, retained the same allele (Table 5 ).
This was consistently observed in the two patients (A6-3807 and A6-5660) with a large amount of LOH in normal colon tissue as well as the remaining 13 patients, suggesting these LOH happened early in the common progenitor cell of normal colon and tumor. The primary differences were that tumor had significantly (P < 0.05, Goodness-offit test) more independent LOH and retained more variant alleles than normal colon tissue. For example, for the 9714 heterozygotes in blood, 918 (9.5%) were homozygotes in the corresponding normal colon while 1583 (16.3%) were homozygotes in tumor (Table 5 ). Among the homozygotes, 100 (10.9%) in normal colon tissue retained the variant allele, and 569 (35.9%) in tumor retained the variant allele.
We captured 39 unique regions of LOH that retained variant alleles in both normal colon tissue and tumor (Table 5 ). A6-3807 had CN-LOH that retained the abnormal stop codon (rs16883571, KHDC1, 6q13). AA-3521 had CN-LOH that retained the abnormal splice site (rs13240848, GALNTL5, 7q36.1). The rest of the 37 LOH were associated with retaining alleles that cause non-synonymous mutation. We captured 511 tumor-specific LOH that retained variant alleles (Table 5 ). Three genes on 18q topped this list of tumor-specific LOH, including include MRO (rs2849233, 18q21.2), DSG1 (rs1426310, 18q12.1), and FECH (rs1041951, 18q21.31) that had either CN-LOH or CL-LOH in five, three, and three patients, respectively.
In the germline variant analysis, one patient (AA-3527) had a homozygous variant allele on rs2228006, which causes gain of stop codon on gene PMS2, a gene involved in MMR. Also, the germline homozygous variant allele associated with stop gain/loss was observed on gene TAS2R46 (rs2708381, 12p13.2) in four patients, KHDC1
(rs16883571, 6q13) or SERPINB11 (rs4940595, 18q21.3) in three patients, and ZNF799 (rs2006651, 19p13.2) in one patient. These same genotypes were observed in the matched normal colon and tumor samples from these patients.
| Validation of LOH and CNV in a model of neoplastic transformation
We sought to verify the LOH and CNV that we discovered in the above TCGA samples in an independent set of patients. Additionally, since we detected aberrations in the blood and normal colon epithelium, we were interested if adenomatous polyps would contain these genetic aberrations as well since they are an early, non-malignant, and precursor legion to CRC. In these cases, we have captured the CRC tissue along with the residual polyp of origin that is contiguous with the cancer, which enables a time lapse model of normal colon to nonmalignant polyp and the contiguous cancer.
We have verified in a total of 13 independent patient samples representing 44 tissues that there are genetic aberrations on 18q as reported in the TCGA data. We found LOH and deletion events at 18q in the precursor polyp and tumor tissue, for patients A02 ( Figure 3A) and A11 ( Figure 3B ). The interspersed LOH was found specifically at the 18q ∼50-85 MB and ∼60-75 MB regions in the polyp tissue of the two samples, respectively. In patient A11, the DCC gene is located at the region of LOH due to the deletion. In the remaining eight patients with either blood or normal colon, we were able to analyze LOH and CNV in the polyp and tumor tissue only. We discovered 18q LOH in both the polyp and tumor tissue in one patient, and 18q LOH due to deletion in the tumors of four of the patients ( Figure S6 ). Since almost half of the CL-LOH and CNV (copy gain) aberrations in normal colon were also found in the blood, CN-LOH actually accounted for the primary difference between blood and normal colon.
It is of note that CN-LOH can be deduced only by comparing to informative loci in the reference sample (ie, heterozygous in blood for this study). Given that somatic changes accumulate in peripheral white blood cells during cell division, 34 the actual amount of CN-LOH in normal colon tissue might be more than what was observed here. More "genuine" sources of germline information for detecting somatic aberrations would be tissues which undergo little to no cell divisionsuch as nervous tissue or even occipital brain tissue. 35 However, these tissue types are not readily obtainable, and for the present, peripheral blood DNA is likely to remain the standard reference sample type.
Our data demonstrated high frequency loss of 18q in sporadic CRC tumors, which is consistent with previous reports. 36 The highest frequency of genetic aberration observed on 18q was in normal colon rather than tumor. This was due to the extent of genetic disruption present in the tumor in which 18q loss affected the whole q arm, while in normal colon, the genetic aberrations spanned only a few kilobases.
Together with the observation that 96.9% of common LOH in normal colon and tumor retained the same allele, these findings suggest that the arm-specific aberrations in macroscopically and histologically normal colon predated the tumorigenic process and possibly promoted the acquisition of genetic changes in tumor. Similar observations were noted in another study, 12 which found a similar aneusomy pattern between sporadic CRC tumor and distal normal colon mucosa.
Importantly, the genetic aberrations we found on 18q in normal colon most frequently overlapped the DCC gene and were also present in the corresponding tumors. DCC encodes a netrin receptor 37 that leads to proliferation and cell migration when bound with netrin-1.
38
The genetic aberrations in DCC may cause a functional change in the DCC protein, which would contribute partly to CRC predisposition, as DCC mutant mice do not develop malignancies. 39, 40 Unfortunately, due to limited SNP coverage here we were not able to cover DCC in the functional SNP analysis.
The highest frequency of genetic aberrations found in blood samples were also on 18q, where a short region with weak copy gain signal was detected in at least two different loci in 10 of the 15 patients with pMMR CRC. In the dMMR patients, there were significantly fewer aberrations found on 18q, but instead had wide spread aberrations on 17, 19, and 22q. These findings confirm genetic aberration differences based on the MMR status of the CRC patient. In six pMMR patients the copy gain overlapped with CCDC102B, a protein-coding gene on 18q22.1 that was most likely to be mutated in the tumors. CCDC102B
has not yet been reported as either a tumor suppressor or promoter gene, and does not overlap with known common copy number polymorphism loci. 41 This implies two possible explanations that require further experimental validation. First, this might be a sporadic pMMR CRC specific germline genetic aberration. Second, this might be a signal from circulating tumor cells. If the latter case is true, it can potentially be used as a "liquid biopsy" marker for sporadic CRC.
In the tumor samples, we found genetic aberrations on several genes that are commonly mutated in blood samples from hereditary CRC (eg, APC, CTNNB1, SMAD4, and BRAF). Although most of them have been shown to be functionally involved in tumorigenesis, their causal relationships with CRC remain elusive. 36 In the current study, none of these genes showed LOH or CNV aberrations in normal colon or blood. Moreover, results from exome sequencing of the normal colon of a patient, neither somatic nor germline mutations were detected in APC or CTNNB1, suggesting the genomic instability seen in colon and blood supports the latter scenario and is also in line with the previously proposed mathematical model. 42 Nevertheless, we are aware that the current methodology captures only a limited fraction of the whole mutation spectrum. Further analysis involving epigenetics data is required to provide a comprehensive evaluation of the aberrations in normal colon or blood from these sporadic CRC patients. Viral infection is another confounding factor to consider, as existing studies have shown it may be associated with LOH in CRC. 43 From this study, we are aware of the potential heterogeneity in macroscopically normal colon tissue, which as of yet cannot be modeled by the statistical framework in the current software package.
We utilized an independent set of patients, which included macrodissected normal colon epithelial tissues (although stromal and mucosal tissue still could be present) to enrich for the purity of the specimen, and did not observe aberrations in these normal tissues.
However, we did observe alterations in the pre-malignant polyp tissues, which are also macrodissected and enriched for the polyp portion of the tissue. Single cell based techniques could be helpful in providing more insight into the current observations.
Our analysis has demonstrated arm-specific enrichment of genetic aberrations on 18q in both normal colon and blood from sporadic CRC patients. It is of interest to note that similar LOH enrichment was also observed in our previous study on breast infiltrating ductal carcinoma distant normal tissue, albeit on different arms. 44 Concurrent with our previous work on NCI-60 cancer cell lines, 45 these findings suggest that these aberrant genetic patterns are tissue specific and may be the precursors for the larger genetic aberrations present in tumor.
We were able to validate our findings by WGS in an independent cohort of patients, which included the precursor polyp tissue in addition to the blood, normal colon, and tumor tissue. Collectively, we have identified genetic aberrations at 18q occurring in the nonmalignant polyp lesion in three patients (23%), and in the tumor tissue of five patients (38%) from the 13 total patients. While we did not observe the 18q LOH in the normal colon tissue in the independent cohort, we did in the non-malignant polyp tissues. This validates our discovery of early genetic aberrations in the TCGA and shows that the genetic aberrations extend into the early lesion of the polyp. Our findings support the hypothesis that CIN may be an early event and therefore causative factor in the tumorigenesis of sporadic CRC. This finding indicates an important role for aberrations at 18q in the development and progression of CRC. The blood, normal colon, and polyp are all readily attainable specimens through a blood-draw or colonoscopy. The ability to detect early molecular aberrations in these pre-malignant samples points to the potential for a blood-based or a normal colon and/or polyp collected at colonoscopy diagnostic marker for assessment of risk for transformation. It will be necessary to evaluate the functional significance and clinical utility of these aberrations in future studies. Our findings further highlight the existence of detectable aberrations in blood, normal colon and polyp tissue that maybe useful as a sporadic CRC risk marker in patient evaluation within the clinical setting.
